TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT03008304

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: High-activity natural killer
Description: Each treatment: 8\~10 billion cells in all, transfuion in 3 times, i.v.
Study: NCT01759238

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Capecitabine
Description: 825mg/m2 per os bid

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bevacizumab
Description: 7.5 mg/kg

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Radiotherapy
Description: (conventional or intensity-modulated and image-guided radiotherapy)
Study: NCT03618810

Intervention type: DRUG
Intervention: PEGCSF first level prophylactic use
Description: 6mg (≥45kg) or 3mg (\<45kg) i.h. once 24h after chemotherapy in all cycles of chemotherapy

Intervention type: DRUG
Intervention: PEGCSF second level prophylactic use
Description: 6mg (≥45kg) or 3mg (\<45kg) i.h. once 24h after chemotherapy in next cycle if FN or 4 grade neutropenia happened
Study: NCT03644615

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Mindfluness and usual care
Description: Intervention based on a mindfulness training program as a therapeutic alternative in osteoarthritis of the knee or hip. Mindfulness is a technique of attention training, which is to focus one's attention on the present moment and to examine the sensations that come to mind, how they appear, how they last time, and how they disappear.

Intervention type: OTHER
Group type: OTHER
Intervention: Usual care
Description: No intervention on the patients
Study: NCT01507402

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: (inactive substance)
Study: NCT02667444

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SB204 4%
Description: Applied topically once daily

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Vehicle Gel
Description: Applied topically one daily
Study: NCT02004743

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Intervention
Description: Psychological guidelines and PET~Patients will receive questionnaires at recruitment, 1 month, 3 months and 6 months based on the timeline of Diagnostic and Statistical Manual (DSM) -IV criteria for PTSD.

Intervention type: OTHER
Group type: OTHER
Intervention: Treatment as usual
Description: Participants will experience treatment as usual.~Patients will receive questionnaires at recruitment, 1 month, 3 months and 6 months based on the timeline of Diagnostic and Statistical Manual (DSM) -IV criteria for PTSD
Study: NCT03086824

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: magnetic resonance-guided focused ultrasound
Study: NCT00999973

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Mitomycin C 0.02%
Study: NCT05040100

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: 3D Mediastinum Model
Description: The 3D model cohort was provided with an additional 10-minute interactive lecture reviewing the same focused mediastinal anatomical structures using the 3D model.
Study: NCT01167634

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Deposit contract with a 1:1 match
Description: Daily weigh-in for 24 weeks and if each daily goal met daily deposit amount is paid back with an additional matched amount equal to deposited amount. Final weigh-in at 36 weeks with no financial incentive or deposit made.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Deposit contract with a 2:1 match
Description: Daily weigh-in for 24 weeks and if each daily goal met daily deposit amount is paid back with an additional matched amount twice the amount equal to deposited amount. Final weigh-in at 36 weeks with no financial incentive or deposit made.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Deposit Contract with no match
Description: Daily weigh-in for 24 weeks and if each daily goal met the daily deposit amount is paid back. Final weigh-in at 36 weeks with no financial incentive or deposit made.
Study: NCT00574223

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CYT005-AllQbG10 (combination of house dust mite allergen extract with CYT003-QbG10)
Description: subcutaneous injections at 8 visits

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: House dust mite allergen extract in combination with CYT003-QbG10-placebo
Description: subcutaneous injections at 8 visits
Study: NCT00939406

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Hyalospine
Description: Intervention group consists of subjects randomized to the treatment arm who will receive lumbar decompression surgery (laminotomy or laminectomy) and HyaloSpine.
Study: NCT02592681

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: verum acupuncture
Description: Participants will receive real needle insertion. Sterile needles will be used on all acupoints. The depth of insertion will vary from 15 mm to 20 mm depending on the exact locations. An initial manual stimulation will be given at insertion by rotation methods to produce a specific sensation described as de-qi in TCM. Then the needles will be left in the acupoint for 20 min, with a manual rotation at 4-8 Hz and an amplitude of approximately 0.5-2 rotations at a ten-min interval to maintain the sensation of de-qi. Primary acupoints used in the verum acupuncture group will be: LR3 (Taichong), LI4 (Hegu), SP6 (Sanyinjiao), GB20 (Fengchi). Extra acupoints will be selected based on TCM pattern are GB41 (Zulinqi), SP10 (Xuehai), KI3 (Taixi), or LR2 (Xingjian).

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: acupressure
Description: The acupoints and the number of the sessions will be exactly the same as for the verum acupuncture group. Acupressure will be applied on all the corresponding acupoints described in the acupuncture group. Finger pressure will be applied to each acupoint for eight seconds followed by two-seconds rest, repeated for 3 min. The strength of the pressure depends on individual participant's sensation of de-qi. Duration of each session will be 15 min.

Intervention type: PROCEDURE
Group type: SHAM_COMPARATOR
Intervention: control acupuncture
Description: The number, duration, and frequency of the sessions will be the same as for the verum acupuncture group. Sterile needles will be used on acupoints that have no therapeutic effect on either menstruation or migraines, based on the acupuncture text books and acupuncture research literature. The points chosen will be: LR7 (Xiguan), GB35 (Yangjiao), LI12 (Zhouliao), M-BW-1 (Dingchuan). The depth of needle insertion will be as superficial as 3 mm, and without manual rotation, in order to minimize stimulation of the needle.
Study: NCT04225000

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Exercise Group
Description: Control group included 6 different exercises to treat participants having PFPS. These exercises included Semi squat with hip adduction and internal rotation, Quads isometrics, Straight Leg Raise (SLR) Hamstring Stretch, Terminal knee extension with elastic band , Adductor squeeze in crook lying (squeeze the ball), Hip abduction in standing with elastic band. These all exercises were advised to perform 3 x 15 Repetitions with 10 sec hold. This exercise protocol was for 4 weeks and 3 sessions per week.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Mobilization Group
Description: Experimental group included Anterior-Posterior (AP) tibiofemoral joint mobilization and all 6 exercises suggested controlled group for treating participants having PFPS; 3 sessions of mobilizations per week and total 4 weeks.~These exercises included Semi squat with hip adduction and internal rotation, Quads isometrics, Straight Leg Raise (SLR) Hamstring Stretch, Terminal knee extension with elastic band , Adductor squeeze in crook lying (squeeze the ball), Hip abduction in standing with elastic band. Theses all exercises were advised to perform 3 x 15 Repetitions with 10 sec hold. This protocol was for 4 weeks and 3 sessions per week.
Study: NCT04759950

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Multicomponent Physical Activity Program
Description: The proposed physical exercise intervention follows the American College of Sports Medicine (ACSM, 2017) and the American Stroke Association (Billinger et al., 2014) recommendations for stroke patients. The five weekly 45-minute sessions are divided into (1) three sessions guided and supervised telematically by a physical exercise specialist and a physiotherapist; (2) and two autonomous exercise sessions. The supervised sessions include exercises to work aerobic capacity, muscle strength and endurance, flexibility, agility, and balance. The intensity of these exercises is prescribed individually according to each participant's initial level and are gradually increased as the program progresses. Participants are encouraged to walk at a similar intensity on autonomous physical exercise days as performed in the guided sessions (moderate intensity), based on the Borg scale of perceived exertion (Borg, 1982).

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Mindfulness-Based Stress Reduction Program
Description: This intervention follows an adaptation of the scheme and instructions of the official Mindfulness-Based Stress Reduction (MBSR) program designed by Jon Kabat-Zinn. It includes body scanning, sitting meditation, and gentle hatha yoga techniques. An accredited mindfulness instructor leads the 12-week online program, which comprises a presentation session, followed by eight intervention sessions (once a week, lasting 2.5 hours) and an intensive practice session interspersed between sessions six and seven. Apart from the supervised session, the therapist asks participants to carry out some independent practice daily.
Study: NCT02735707

Intervention type: DRUG
Group type: OTHER
Intervention: Local standard venous thromboprophylaxis
Description: Standard venous thromboprophylaxis that complies with local guidelines or usual practice will be administered for 14 days following randomisation or until hospital discharge, whichever occurs first.~Note: this intervention is now closed.

Intervention type: DRUG
Group type: OTHER
Intervention: Therapeutic dose anticoagulation
Description: Patients will be administered either low molecular weight heparin (LMWH) or unfractionated heparin (UFH) to achieve systemic anticoagulation. Either agent may be used and the same patient may be switched between UFH and LMWH at the discretion of the treating clinician.~Note: this intervention is now closed.

Intervention type: DRUG
Group type: OTHER
Intervention: Conventional low dose thromboprophylaxis
Description: Low dose thromboprophylaxis will be administered for 14 days following randomisation or until hospital discharge, whichever occurs first. Dosing is outlined in the relevant protocol documents for this domain.

Intervention type: DRUG
Group type: OTHER
Intervention: Intermediate dose thromboprophylaxis
Description: Intermediate dose thromboprophylaxis will be administered for 14 days following randomisation or until hospital discharge, whichever occurs first. Dosing is outlined in the relevant protocol documents for this domain.

Intervention type: DRUG
Group type: OTHER
Intervention: Continuation of therapeutic dose anticoagulation
Description: Patients already receiving therapeutic dose anticoagulation at the time of randomisation to this intervention will be administered either unfractionated heparin by IV infusion or low-molecular weight heparin to achieve systemic anticoagulation according to local practice for acute VTE treatment for 14 days following randomisation or until hospital discharge, whichever occurs first.~Note: this intervention is now closed.

Intervention type: OTHER
Group type: OTHER
Intervention: No immunoglobulin
Description: No immunoglobulin intended to be active against SARS-CoV-2 infection is to be administered.

Intervention type: BIOLOGICAL
Group type: OTHER
Intervention: Convalescent plasma
Description: Patients will receive at least one and no more than two units of ABO compatible convalescent plasma within 48 hours of randomisation.

Intervention type: BIOLOGICAL
Group type: OTHER
Intervention: Delayed administration of convalescent plasma
Description: Note: this intervention is now closed.

Intervention type: OTHER
Group type: OTHER
Intervention: No vitamin C
Description: No high dose intravenous vitamin C is to be administered~Note: this intervention is now closed.

Intervention type: DRUG
Group type: OTHER
Intervention: Vitamin C
Description: Intravenous Vitamin C 50mg/kg administered every 6 hours for 16 doses~Note: this intervention is now closed.
Study: NCT04759950

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Computerized Cognitive Training
Description: An accredited neuropsychologist programs and supervises the computerized cognitive training through the Guttmann Neuropersonal Trainer (GNPT®) platform. The 12-week program consists of five sessions a week (45 minutes each) that include personalized activities planned to stimulate executive functioning, attention, processing speed, and memory.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Computerized Cognitive Training
Description: An accredited neuropsychologist programs and supervises the computerized cognitive training through the Guttmann Neuropersonal Trainer (GNPT®) platform. The 12-week program consists of five sessions a week (45 minutes each) that include personalized activities planned to stimulate executive functioning, attention, processing speed, and memory.
Study: NCT00999973

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study: NCT01614574

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: velaglucerase alfa
Description: 60 U/kg every other week intravenous infusion
Study: NCT02894320

Intervention type: BEHAVIORAL
Intervention: Behavioral observation

Intervention type: BEHAVIORAL
Intervention: Behavioral observation
Study: NCT03915119

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: GFT AI training
Description: navigates a cluttered environment of stationary and moving/pursuing virtual obstacles to reach a way-point as quickly and efficiently as possible. Block order and difficulty, as well as the behavior of the obstacles in each block, will be driven by the AI and statistically weighted to specifically target the perceptual-motor and neuromechanical mechanisms based on each athlete's visit 1 performance

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: GFT AI training
Description: navigates a cluttered environment of stationary and moving/pursuing virtual obstacles to reach a way-point as quickly and efficiently as possible. Block order and difficulty, as well as the behavior of the obstacles in each block, will be driven by the AI and statistically weighted to specifically target the perceptual-motor and neuromechanical mechanisms based on each athlete's visit 1 performance
Study: NCT02875561

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Sonopet Ultrasonic Aspirator
Description: To evaluate the incident of recurrence of VIN dysplasia events in women treated for VIN with the sonopet ultrasonic aspirator compared to CO2 Laser Ablation

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: CO2 Laser Ablation
Description: To evaluate the incident of recurrence of VIN dysplasia events in women treated for VIN with the sonopet ultrasonic aspirator compared to CO2 Laser Ablation
Study: NCT02836327

Intervention type: OTHER
Intervention: Magnetic Resonance Imaging
Description: Magnetic Resonance Imaging

Intervention type: OTHER
Intervention: Magnetic Resonance Imaging
Description: Magnetic Resonance Imaging

Intervention type: OTHER
Intervention: Magnetic Resonance Imaging
Description: Magnetic Resonance Imaging
Study: NCT02401958

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Resistance training
Description: 17 volunteers with RA and 17 without the disease, with a mean age of 54.7 + 6.63 underwent a resistance exercise session with a set of 12 repetitions at 50% of one repetition maximum (1RM ) and a set of 8 repetitions at 75% of 1RM. The exercises performed were: knee extension, knee flexion, hip abduction and hip adduction. Blood samples were obtained 30 minutes before, 5 minutes before, immediately after, 1 hour, 2 hours and 24 hours after the exercise session.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Resistance training
Description: 17 volunteers with RA and 17 without the disease, with a mean age of 54.7 + 6.63 underwent a resistance exercise session with a set of 12 repetitions at 50% of one repetition maximum (1RM ) and a set of 8 repetitions at 75% of 1RM. The exercises performed were: knee extension, knee flexion, hip abduction and hip adduction. Blood samples were obtained 30 minutes before, 5 minutes before, immediately after, 1 hour, 2 hours and 24 hours after the exercise session.
Study: NCT01168674

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: ziprasidone
Description: Ziprasidone will be administered as a pill. The once-daily total daily dose will be 80-160 mg/d of ziprasidone. Dosing will begin at 20 mg BID with an escalation strategy based on target symptoms and tolerability, with a target dose range of 80-160 mg/d. Dose escalations will occur by increments of 20-40 mg weekly.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Sugar pill
Description: The once-daily total daily dose will be 80-160 mg/d of the sugar pill. Dosing will begin at 20 mg BID with an escalation strategy based on target symptoms and tolerability, with a target dose range of 80-160 mg/d. Dose escalations will occur by increments of 20-40 mg weekly.
Study: NCT03124628

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Flywheel resistance exercise
Description: Flywheel resistance exercise, originally designed to maintain function, size and quality of skeletal muscle during spaceflight, employs iso-inertial technology rather than gravity dependent weights, which allows for coupled accommodated concentric and eccentric muscle actions, and brief episodes of eccentric overload.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Weight-stack resistance exercise
Description: Conventional weight-stack resistance exercise
Study: NCT04029558

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Combination of Plant Extracts (BSL_EP025)
Description: Each participant will consume 2 capsules daily at lunch for 8 weeks.

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Each participant will consume 2 capsules daily at lunch for 8 weeks.
Study: NCT00469781

Intervention type: DRUG
Group type: OTHER
Intervention: 2. Xibrom (Bromfenac)
Description: Group 1 and 2: 1 drop(Instill one drop in the eye that was operated on twice daily)3 days prior to surgery and 4 doses during dilation immediately before the procedure. Use for 4 weeks after surgery.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: 1. Pred Forte
Description: Group 1 Instill one drop in the eye that was operated on four times a day starting on day of surgery and use for four weeks.~Group 2 Instill one drop in the eye that was operated on twice a day starting on day of surgery and use for four weeks.
Study: NCT01923428

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AZD1722

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AZD1722

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AZD1722

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study: NCT02076685

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: isoniazid
Description: dose adjustment according to the pharmacogenomic results
Study: NCT04268953

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tricaprilin
Description: Tricaprilin formulated as AC-SD-03 mixed in 300mL water
Study: NCT03253770

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: SIMMAX2
Description: Digital cognitive aid or paper cognitive aid during the management of a cardiac arrest in the recovery room or in the delivery room.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: SIMMAX2
Description: Digital cognitive aid or paper cognitive aid during the management of a cardiac arrest in the recovery room or in the delivery room.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: SIMMAX2
Description: Digital cognitive aid or paper cognitive aid during the management of a cardiac arrest in the recovery room or in the delivery room.
Study: NCT03989791

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: absolute diet
Description: Patients in absolute diet group were fasted from any food with intravenous infusion of 5% glucose and sodium chloride instead in the first 24 hours. Then, the patients will be given soup for the next 24 hours if there was no delayed complication or discomfort during the fasting. Finally, they will gradually transit from soup to normal diet such as porridge, noodles and rice in the third 24 hours.

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: normal diet
Description: Patients in normal diet group were directly given normal diet such as porridge, noodles and rice as usual after polypectomy. Meanwhile, all the patients in two groups were given PPI for 3 days intravenously and restricted from vigorous exercise for 14 days.
Study: NCT00589550

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: PEG-interferon alfa-2b
Description: administered SC on day 1 of each week of therapy. This will most likely be a Monday or a Tuesday. Sorafenib will be initiated on day 15 (start of week 3) of the first course and continued daily without breaks.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sorafenib

Intervention type: GENETIC
Group type: EXPERIMENTAL
Intervention: gene expression analysis

Intervention type: GENETIC
Group type: EXPERIMENTAL
Intervention: polymerase chain reaction

Intervention type: GENETIC
Group type: EXPERIMENTAL
Intervention: reverse transcriptase-polymerase chain reaction

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: flow cytometry

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: immunoenzyme technique

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: laboratory biomarker analysis
Study: NCT03684005

Intervention type: OTHER
Group type: OTHER
Intervention: MyPatientPal smartphone app
Description: All patients in this single-arm study will use a smartphone-based app, MyPatientPal, to enter symptoms and track medications related to their cancer treatment. No drugs will be administered for the purposes of this behavioral study.
Study: NCT01023880

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CEP-18770
Description: CEP-18770 beginning at a dose of 1.5 mg/m2. Patients will receive I.V. administration on days 1, 8, 15 (up to 8 cycles of 28 days each). When the MTD is established, additional patients will be treated at the MTD.
Study: NCT03514264

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Gutta Percha and AHPLUS cement (group A)
Description: First intervention: endodontic instrumentation and introduction of intact medication that will remain inside the tooth for 4 weeks.~Second intervention: removal of intracanal medication and canal filling with cement AHPLUS and guttapercha

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: PBS CIMMO cement (group B)
Description: Single intervention: endodontic instrumentation and obturation with cement PBS CIMMO